Dystonia

• 

  Subject Areas on Research

  • A Gain-of-Function Mutation in KCNMA1 Causes Dystonia Spells Controlled With Stimulant Therapy. 
  • A novel presentation of DYT 16: acute onset in infancy and association with MRI abnormalities. 
  • Abnormal cerebellar signaling induces dystonia in mice. 
  • Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. 
  • Cholinesterase inhibitors and Pisa syndrome: a pharmacovigilance study. 
  • Comparison of Deep Brain Stimulation Lead Targeting Accuracy and Procedure Duration between 1.5- and 3-Tesla Interventional Magnetic Resonance Imaging Systems: An Initial 12-Month Experience. 
  • Deep brain stimulation as a mode of treatment of early onset pantothenate kinase-associated neurodegeneration. 
  • Defining research priorities in dystonia. 
  • Drug-induced dystonia in neuronal ceroid-lipofuscinosis. 
  • Dysphagia in the setting of left ventricular assist device hemolysis. 
  • Dystonia with and without deafness is caused by TIMM8A mutation. 
  • Elevated plasma phenylalanine in severe malaria and implications for pathophysiology of neurological complications. 
  • Evaluation and treatment of dystonia. 
  • Experimental dystonia induced by quaternary-chlorpromazine. 
  • Functional Genomic Analyses of Mendelian and Sporadic Disease Identify Impaired eIF2α Signaling as a Generalizable Mechanism for Dystonia. 
  • Glutaric acidemia, type I, missed by newborn screening in an infant with dystonia following promethazine administration. 
  • Laryngeal dystonia causing inspiratory stridor in children with cerebral palsy. 
  • Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. 
  • Mouse model of rare TOR1A variant found in sporadic focal dystonia impairs domains affected in DYT1 dystonia patients and animal models. 
  • Myoclonus and tremor response to thalamic deep brain stimulation parameters in a patient with inherited myoclonus-dystonia syndrome. 
  • Safety considerations for deep brain stimulation: review and analysis. 
  • The HIV protease inhibitor, ritonavir, corrects diverse brain phenotypes across development in mouse model of DYT-TOR1A dystonia. 
  • Torticollis acquired in late infancy due to a cerebellar gangliocytoma. 
  • Tourettism and dystonia after subcortical stroke. 
  • Treatment of diaphragmatic dystonia with pallidal deep brain stimulation. 
• 

  Keywords of People

  • Bukhari-Parlakturk, Noreen, Assistant Professor of Neurology, Duke Institute for Brain Sciences
  • Calakos, Nicole, Lincoln Financial Group Distinguished Professor of Neurobiology, Duke Science & Society
  • Milano, Carmelo Alessio, Professor of Surgery, Surgery, Cardiovascular and Thoracic Surgery
  • Turner, Dennis Alan, Professor of Neurosurgery, Biomedical Engineering